Back to Agenda
Combination Products Under Article 117 of the MDR – Alignment on Strategies for Building an Innovative Regulatory Environment in the EU
Session Chair(s)
Thomas Wejs Møller, MBA, MSc
Senior Director Global Regulatory Affairs - Devices, Novo Nordisk, Denmark
Article 117 of the Medical Device Regulation (MDR) is a complex regulatory pathway for approving integral drug-device combination products. Approval of drug-device combination products requires the involvement of Notified Bodies, and EMA providing additional layers of scrutiny. Moreover, changes to combination products under Article 117 present challenges due to a lack of consistency and predictability. The intricate interplay between pharmaceutical and medical device regulations under Article 117 creates uncertainties, contributing to regulatory burdens and hindering the efficient market entry of combination products. This session will convene relevant stakeholders to discuss the challenges associated with Article 117 and collectively develop perspectives aimed at addressing these issues in the EU.
Speaker(s)
Michael Kühler
Senior RA MD Expert, Bayer AG, Germany
Specific Challenges Identified
Paul Piscoi
Scientific Policy Officer, European Commission (EC), Belgium
Panel Discussion:
Christelle Bouygues, PharmD
Senior Regulatory Affairs Officer, European Medicines Agency, Netherlands
Panel Discussion:
Jonathan Sutch, PhD
Principal Medicinal Technical Specialist, BSI Group, United Kingdom
Panel Discussion:
Have an account?